ABSTRACT
Every year, approximately 200 million surgeries are performed worldwide, and intraoperative adverse events (iAEs) have a significant impact on patients and surgeons. Despite their importance, the true scale of iAEs remains underestimated due to inadequate methods for assessment, collection, grading, and reporting. Various grading systems have been introduced over the past decade, but their adoption has been limited, leading to inconsistencies in reporting. Furthermore, a lack of standardized frameworks for defining, assessing, and collecting iAEs, coupled with litigation concerns, contributes to underreporting. Only half of surgery and anesthesiology journals provide guidance on reporting perioperative adverse events, and recommendations for reporting iAEs are notably lacking in surgical literature. To address these issues, the Intraoperative Complications Assessment and Reporting with Universal Standard (ICARUS) Global Surgical Collaboration was established in 2022. The initiative involves conducting global surveys and a Delphi consensus to understand the barriers for poor reporting of iAEs, validate shared criteria for reporting, define iAEs according to surgical procedures, evaluate the existing grading systems’ reliability, and identify strategies for enhancing the collection, reporting, and management of iAEs. A sample size of 2,398 respondents was calculated for the study, with invitations extended to 86,574 healthcare providers. This effort represents an essential step towards improved patient safety and the well-being of healthcare professionals in the surgical field.
Competing Interest Statement
Mihir M. Desai is a proctor for PROCEPT BioRobotics. Inderbir S. Gill is an unpaid advisor for Steba and has equity interest in OneLine Health. Andre Luis Abreu is a consultant for Koelis and Quibim, and speaker for EDAP. Other authors do not have any competing interests.
Clinical Trial
NCT04994392 and NCT05270603
Clinical Protocols
https://doi.org/10.17605/OSF.IO/NDQ4F
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This Institutional Review Board of University of Southern California gave ethical approval for this work (UP-21-00473 and UP-21-01010). This study is registered to ClinicalTrials.gov (NCT04994392 and NCT05270603).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
